Payment overview · 2025
General Payments
$1,026.96
46 reported records · 12 companies
Healthcare provider profile · identity verified
Matthew Trzesniowski, D.O.
Allopathic & Osteopathic Physicians|General Practice · PHILADELPHIA, PA · NPI 1487933503
Verified facts
What the public records show
CMS Open Payments records show Matthew Trzesniowski, D.O. received $1,026.96 in general payments during 2025 across 46 reported records.
ABBVIE INC. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $226.15 | 22.0% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $220.51 | 21.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.28 | 14.9% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $113.91 | 11.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.25 | 6.3% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $64.39 | 6.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.08 | 4.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.93 | 3.7% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $31.74 | 3.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.27 | 2.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.38 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.07 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,026.96 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $176.67 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $155.30 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $130.27 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $119.56 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $113.91 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.85 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $64.39 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $60.35 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.10 | 3 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $43.84 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.93 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $37.93 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $26.27 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 97 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
146 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 987 | 230 |
| Amlodipine Besylate | Amlodipine Besylate | 790 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 604 | 133 |
| Lisinopril | Lisinopril | 588 | 142 |
| Alprazolam | Alprazolam | 506 | 70 |
| Metformin Hcl | Metformin Hcl | 501 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 494 | 109 |
| Losartan Potassium | Losartan Potassium | 486 | 116 |
| Omeprazole | Omeprazole | 482 | 111 |
| Lorazepam | Lorazepam | 469 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 440 | 79 |
| Ibuprofen | Ibuprofen | 405 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 397 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 385 | 100 |
| Fluticasone Propionate | Fluticasone Propionate | 317 | 93 |
| Gabapentin | Gabapentin | 276 | 66 |
| Simvastatin | Simvastatin | 269 | 73 |
| Furosemide | Furosemide | 263 | 72 |
| Famotidine | Famotidine | 253 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 213 | 59 |
| Alendronate Sodium | Alendronate Sodium | 209 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 204 | 23 |
| Azithromycin | Azithromycin | 197 | 124 |
| Oxycodone Hcl | Oxycodone Hcl | 188 | 21 |
| Sertraline Hcl | Sertraline Hcl | 182 | 35 |
| Carvedilol | Carvedilol | 178 | 36 |
| Tramadol Hcl | Tramadol Hcl | 175 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 57 |
| Prednisone | Prednisone | 170 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 43 |
| Clonazepam | Clonazepam | 158 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 151 | 20 |
| Diazepam | Diazepam | 150 | 25 |
| Methylprednisolone | Methylprednisolone | 148 | 98 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 147 | 20 |
| Eliquis | Apixaban | 146 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 39 |
| Allopurinol | Allopurinol | 122 | 27 |
| Xarelto | Rivaroxaban | 115 | 20 |
| Trazodone Hcl | Trazodone Hcl | 110 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 19 |
| Lovastatin | Lovastatin | 103 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 29 |
| Jardiance | Empagliflozin | 97 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 20 |
| Montelukast Sodium | Montelukast Sodium | 93 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 26 |
| Pregabalin | Pregabalin | 93 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 92 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 24 |
| Ozempic | Semaglutide | 88 | 18 |
| Potassium Chloride | Potassium Chloride | 87 | 16 |
| Atenolol | Atenolol | 86 | 21 |
| Enalapril Maleate | Enalapril Maleate | 85 | 19 |
| Ezetimibe | Ezetimibe | 85 | 23 |
| Meloxicam | Meloxicam | 85 | 18 |
| Warfarin Sodium | Warfarin Sodium | 85 | 16 |
| Trulicity | Dulaglutide | 84 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 79 | 53 |
| Mounjaro | Tirzepatide | 78 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 33 |
| Baclofen | Baclofen | 74 | 16 |
| Buspirone Hcl | Buspirone Hcl | 73 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 14 |
| Celecoxib | Celecoxib | 65 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 16 |
| Meclizine Hcl | Meclizine Hcl | 64 | 18 |
| Nifedipine Er | Nifedipine | 64 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | suppressed |
| Temazepam | Temazepam | 61 | suppressed |
| Aripiprazole | Aripiprazole | 59 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | suppressed |
| Glimepiride | Glimepiride | 58 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | suppressed |
| Cephalexin | Cephalexin | 57 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 12 |
| Metformin Hcl Er | Metformin Hcl | 55 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 12 |
| Valacyclovir | Valacyclovir Hcl | 54 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 13 |
| Glipizide Er | Glipizide | 51 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 15 |
| Bupropion Xl | Bupropion Hcl | 50 | 13 |
| Naproxen | Naproxen | 50 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | 12 |
| Glipizide | Glipizide | 48 | 13 |
| Spironolactone | Spironolactone | 48 | suppressed |
| Lidocaine | Lidocaine | 47 | 13 |
| Farxiga | Dapagliflozin Propanediol | 45 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 24 |
| Finasteride | Finasteride | 42 | 14 |
| Ketoconazole | Ketoconazole | 42 | 18 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 22 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Loperamide | Loperamide Hcl | 37 | 11 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | 11 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 26 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | 12 |
| Dutasteride | Dutasteride | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 24 | 11 |
| Digoxin | Digoxin | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,026.96 · 46 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, COMIRNATY, CONTRAVE, EVENITY, FARXIGA, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, JOT DX, MOUNJARO, Ozempic, PREVNAR 20, PROLIA, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, YUPELRI, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error